Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
about
Interplay between Cellular and Molecular Inflammatory Mediators in Lung CancerNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialUpdates in Therapy for Advanced MelanomaClinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysisTiming and extent of response in colorectal cancer: critical review of current data and implication for future trialsNivolumab in the treatment of malignant melanoma: review of the literatureTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsThe prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis.Novel immune checkpoint blocker approved for the treatment of advanced melanomaThe Characterization of Varicella Zoster Virus-Specific T Cells in Skin and Blood during Aging.Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysisMultistep, effective drug distribution within solid tumors.Implementation of modern therapy approaches and research for non-small cell lung cancer in Japan.New clinical advances in immunotherapy for the treatment of solid tumours.Immune checkpoint therapy for non-small-cell lung cancer: an update.Emerging immunotherapy for the treatment of esophageal cancer.Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load.Radiotherapy and immunotherapy: a beneficial liaison?Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials.Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis.Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma.Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysisPD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes.miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles.How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Trial watch: Immune checkpoint blockers for cancer therapy.89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding.
P2860
Q26768652-90DE5D6C-8B81-4B7F-801C-35303BD96578Q26769884-4CEB765A-330C-447B-98FF-1D8602DF99EFQ26771119-D6A1DC0F-698F-4A6A-88AE-3EB4686B2FE4Q26775460-25E8388D-1246-4ACF-9C33-7750B409CB68Q26797292-DD3F294E-ACE2-408F-B055-86E08F551F60Q26798330-774289A6-C86E-4A9F-9FF9-2BA95720C39DQ26996518-83011A30-E48E-425C-B0D2-A3B78472CCE5Q33835174-38A9C11D-9DBC-4BBC-9F92-DA57D205167BQ34936394-5CAEAE5E-2839-40D0-92F2-317E58784F0CQ35752877-A954A270-ECD5-41E0-B780-0FE40AEDB29EQ36260666-3488C20F-F639-4E11-A0F3-2F888A6F5AE8Q36303134-BB297EBD-7ACC-43B1-86AA-85AD82CF3360Q36891533-52A0D5C2-9232-41DF-B6FE-634E7E447C4AQ38261634-84AD68E0-9479-4E1C-9917-FB415196A5B8Q38320914-71FBCFE3-19C5-4C39-B1E8-F177700C20A6Q38397279-F48306D7-CEAC-422B-892E-D1B62EFFC80BQ38727542-6209B0F6-C7C1-4F2B-AE97-9ADF218EBE7BQ38763851-88FFA55B-C6B3-4BC7-80BA-8A21EC5A720CQ38783026-677A7B1B-E30D-485E-B286-21F756F4A251Q38920328-D97121D8-1ACD-4723-9B46-59D95EE7DC18Q38931346-BD60DE3D-1160-4A7E-B3FB-34351BF31A01Q39017268-6E2C1FFB-6DDD-452F-87C8-FC2DC34B69B0Q39215902-CBB6F563-19EE-4733-A10B-14BFC839E1B5Q39308716-55FB07E9-5613-4BC4-AD25-0C37141CCB56Q41145904-DF2BFD43-C0FE-4673-B9B8-72288FCAB077Q41302377-2AE3EDBC-DD93-4549-94CE-F6E1310C2BF3Q41445876-A0278F3C-7871-4EAD-A438-98FFE07E3315Q41612699-7B5ED18F-50F3-4DB7-9CDF-A4016B48C340Q41992370-6F0C54D4-C78D-4DE8-8406-B4D8A26188D0Q42558833-6F2DADDF-0EED-455C-8C85-AF78F8FEB03AQ47093855-A70B6474-C661-44FB-90A1-0338B56FF292Q47120953-396AC394-92AB-4A57-BD90-5BA28462A5AEQ47221234-EB714D43-2F87-4ED4-A20F-5044C14A22C7Q47393365-04CF4CC3-F92B-48A3-A733-60C6E31DC555Q55362101-7031B168-365D-4192-90B1-97AD979CEF74
P2860
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
@en
type
label
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
@en
prefLabel
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
@en
P2093
P2860
P356
P1476
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
@en
P2093
Linda Lee-Gabel
Michelle C Nadeau
Scott A Soefje
Thomas M Ferencz
P2860
P304
P356
10.1177/1078155214538087
P577
2014-06-09T00:00:00Z